TikoMed’s ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS
VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed's ILB® neuroprotective drug platform. In multiple preclinical and clinical studies across a variety...
NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421
TAIPEI, Aug. 31, 2022 /PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of this study is to assess the safety and antiviral activity of UB-421 in combination...
NuraLogix researchers announce AI models that can predict Blood Biomarker Risk
TORONTO, Aug. 31, 2022 /PRNewswire/ -- Researchers at NuraLogix, a global leader in HealthTech AI, announced today that they have developed AI models that can predict a person's risk of HbA1C levels and Fasting Blood Glucose levels being above a significant clinical threshold for pre-diabetes. This is important because it will someday allow people to screen themselves using any...
Pet Telemedicine Platform Pawlyclinic Expands to Indonesia To Make Veterinary Care More Easily Accessible Across Southeast Asia
A one-stop platform that is redefining veterinary care, Pawlyclinic features various services, from teleconsultation to seamless access to medical records so that that pet parents can safeguard the health of their pets JAKARTA, Indonesia, Aug. 31, 2022 /PRNewswire/ -- Singapore-based pet telemedicine platform, Pawlyclinic, announces its expansion into the Indonesian market, providing...
Fosun International Announces 2022 Interim Results: Total Revenue Amounted to RMB82.89 Billion, representing a year-on-year increase of 17.7%
HONG KONG, Aug. 31, 2022 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its financial results for the six months ended 30 June 2022 (the "Reporting Period"). In the first half of 2022, against the backdrop of the complex and volatile external environment, Fosun demonstrated the...
Nreal Air AR Glasses Receive TÜV Rheinland Eye Comfort (AR) Certification
SHANGHAI, Aug. 31, 2022 /PRNewswire/ -- On August 22, 2022, TÜV Rheinland Greater China ("TÜV Rheinland") awarded the Eye Comfort (AR) Certification for Nreal's AR glasses, Nreal Air, ahead of the device's official launch in China. The bestowal of TÜV Rheinland's highest-level display certification for AR devices to Nreal Air follows Nreal's...
GC Biopharma and Speragen Sponsored an Externally Led – Patient Focused Drug Development with FDA Attendance
YONGIN, South Korea and AUSTIN, Texas, Aug. 30 2022 /PRNewswire/ -- GC Biopharma (006280.KS) and Speragen today announced that a joint Externally Led - Patient-Focused Drug Development (EL-PFDD) meeting hosted by SSADH Association and attended by the U.S. FDA and other stakeholders was held to address the patient experience with SSADHD (Succinic Semialdehyde...
Antengene Announces Interim 2022 Financial Results and Provides Corporate Update
- Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Mainland China on May 13, 2022 - Adjusted loss reduced to RMB 126 million for the first six months of 2022 from RMB 210 million in the same period last year - Cash and bank balances of RMB...
Biomedical industry bears fruit again in National Nanning Economic & Technological Development Area
NANNING, China, Aug. 31, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by Guangxi Yizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic & Technological Development Area ("Area") has been granted the registration certificate of class III medical devices (GXZZ20223210687). Production workshop of Nanning Neptunus Health Industrial Park Nanning's investment promotion...
Tycoon Group Announces 2022 Interim Results
Dual-Channel Drive Strategy Brought a Record-High Revenue of 588 Million & Rebound with 22.8 Million Profit The Group Continues to Explore the Blue Ocean Market in China Results Highlights The Group taking the lead in developing cross-border e-commerce business and adopting an online and offline dual-channel drive strategy have achieved with results. Revenue of the Group for 1H2022...
